KRAS and cancer: KRAS G12C mutation has been on the radar of cancer researchers since 40 years ago, but drug development for this target has been slow that it was once considered a “non-druggable target.” However, since 2013, several selective and irreversible inhibitors targeting KRAS G12C mutation, which occurs in about 3%–4% of mCRC patients, have been under development (Jones et al., 2017).